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ABSTRACT 
We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, 
a Southern European country exposed to intense recent flux migration from endemic 
areas for SCD. We evaluate the impact of hydroxyurea on a  total of 652 pediatric 
and adult patients from 33 Reference Centers for SCD (mean age 24.5 ± 15 years, 
51.4% males). Hydroxyurea median treatment duration was 7 years (range: <1 year 
to 29 years) at a mean therapeutic dose of 18 ± 4.7 mg/kg/day. Hydroxyurea was 
associated with a significant increase in mean total and fetal hemoglobin and a 
significant decrease in mean hemoglobin S, white blood and platelet counts, and 
lactate dehydrogenase levels. Hydroxyurea was associated with a significant 
reduction in the incidence of acute chest syndrome (-29.3%, p<0.001), vaso-
occlusive crisis (-34.1%, p<0.001), hospitalization (-53.2%, p<0.001), and bone 
necrosis (-6.9%, p<0.001). New silent cerebral infarction (SCI) occurred during 
treatment (+42.4%, p<0.001) but not stroke (+0.5%, p=0.572). These observations 
were generally consistent upon stratification for age, descent (Caucasian or African), 
genotype (βS/βS, βS/β0 or βS/β+) and duration of treatment (< or ≥10 years). There 
were no new safety concerns observed compared to those commonly reported in the 
literature. Our study, conducted on a large population of patients with different 
descent and compound state supports the benefits of hydroxyurea therapy as a 
treatment option. Registered at clinical trials.gov (NCT02709681). 
 
Keywords: hydroxycarbamide, management, real-world, complications. 
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INTRODUCTION 
With the ongoing search for targeted and curative therapeutics for sickle cell disease 
(SCD) and its manifestations, hydroxyurea remains a cornerstone of conventional 
management owing to its oral efficacy and low toxicity [1,2].  The disease modifying 
properties of hydroxyurea were initially attributed to its ability to induce fetal 
hemoglobin and decrease hemoglobin S polymerization [3,4].  which should 
theoretically ameliorate downstream pathophysiologic mechanisms, acute and long-
term clinical morbidity. Other beneficial effects have subsequently emerged including 
increasing total hemoglobin levels, decreasing platelet and white blood cell counts, 
changing expression of adhesion molecules, and nitric oxide generation [1,5,6].  
Thirty years of clinical experience through randomized clinical trials and large 
observational studies established that hydroxyurea is safe and effective in 
decreasing the frequency of acute complications like painful vaso-occlusive crisis 
and acute chest syndrome, while also decreasing the need for blood transfusion and 
hospitalization in SCD adults and children as young 9 months of age [7-13]. Long-
term follow-up studies have also established continued benefit as well as reduction 
in mortality [14-17]. In addition, the initial concerns on HU effects on fertility and 
carcinogenic potential have not been fully established in patients with SCD and 
require a long-term follow-up on large cohorts of SCD patients [7-13].  Despite such 
substantial body of evidence, hydroxyurea is considered an underutilized medication 
in SCD [1,13,18].  Thus, data from real-life experiences with hydroxyurea remain 
essential to further illustrate the role of this intervention to practicing clinicians.  
 
Until the last decade, SCD was endemic in Southern Italy (Sicily and Calabria) with 
limited number of patients spread all over the country due to internal migration. Thus, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
data on the epidemiology and clinical profile of SCD in Italy, as Southern European 
country exposed to intense migration fluxes from areas endemic for SCD, such as 
the Sub-Saharian countries [19] , have been deeply changed. Such current and 
future mobility and migration flows, pose considerable new challenges that have to 
be taken into consideration by member states and EU authorities primarily through 
collection of data from existing patients. 
 
With this background, the aim of this study was to report the first, real-life experience 
with the use of hydroxyurea in a large cohort of SCD patients with heterogeneous 
descent and different compound state. 
 
METHODS 
This was a retrospective cohort study of SCD patients attending treatment centers 
across Italy. All Italian Hematology Centers part of the Italian Society of Thalassemia 
and Hemoglobinopathies (SITE) and all Pediatric Hematology Oncology Units part of 
the Italian Association of Pediatric Hematology Oncology (AIEOP) were invited to 
participate in the study. Invitation was expressed during two meetings of the Working 
Groups and by a letter. All large Regional Reference Centers (pediatric and adult)  
for therapy of SCD participate to study. Out of 1638 patients registered at 33 
participating centers, 652 (39,8%) patients had received hydroxyurea therapy for 
some period throughout their disease course and were included in this analysis. The 
indication for hydroxyurea initiation was 2-3 vaso-occlusive crisis and/or acute chest 
syndrome in the year prior. Hydroxyurea was initiated at a starting dose of 10 
mg/kg/day, and adjusted or escalated according to tolerance. For each patient, 
retrieved data included demographics (age and gender), origin, genotype, and folic 
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acid use. The duration of treatment (until discontinuation or death) and average 
hydroxyurea dose throughout therapy were also recorded. We also retrieved 
average of all available laboratory values up to three years pre-hydroxyurea and for 
the period on-hydroxyurea therapy including total hemoglobin level, fetal hemoglobin 
level, hemoglobin S level, white blood count, platelet count, lactate dehydrogenase 
level, total and direct bilirubin levels, aspartate and alanine aminotransferase levels, 
and serum creatinine level. The incidence of new complications pre- and on-
hydroxyurea therapy was also retrieved as available from medical records and as 
defined by internationally recognized criteria [20], including: stroke, silent cerebral 
infraction, acute chest syndrome, vaso-occlusive crisis, hospitalization, leg ulcers, 
pulmonary hypertension defined as patients with a tricuspid-valve regurgitant jet 
velocity ≥3.2 m/s (3.6%) on transthoracic echocardiography further underwent right 
heart catheterization to confirm the diagnosis of PAH (mean pulmonary arterial 
pressure ≥25 mm Hg and pulmonary capillary wedge pressure ≤15mm Hg) 
[21,33,34,35], AVN defined as  bone necrosis confirmed by radiographs and in some 
cases MRI and  chronic kidney disease was defined according to the National 
Kidney Foundation, Kidney Disease Outcomes Quality Initiatives (K/DOQI) 
guidelines. [22]. For silent cerebral infarction, only patients with magnetic resonance 
imaging performed within the last ten years were considered to limit the chance of 
varying imaging methodology. In such patients screening scans were repeated every 
two years. For acute chest syndrome, vaso-occlusive crisis and hospitalization, aside 
from incidence the average number of episodes per year (to the nearest integer) 
were collected up to three years pre-hydroxyurea and for the period on-hydroxyurea. 
Safety data included adverse events as reported by the treating physician and the 
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incidence of malignancy or death. Pregnancy incidents and their outcomes were also 
collected. 
 
The study was approved by the ethical committee of Palermo 2 and the study was 
registered at clinical trials.gov (NCT02709681). 
 
Statistical analysis 
Descriptive data were reported as mean ± standard deviation, median (range), or 
percentages. Bivariate comparisons of laboratory and clinical data pre- and on-
hydroxyurea were done using the paired-samples t-test for means, Wilcoxon 
matched-pair single-rank test for medians, and McNemar’s test for percentages. 
Spearman’s correlation (r) coefficient was used to evaluate correlations between 
hydroxyurea dose and changes in laboratory parameters. A Kaplan Meier curve was 
drawn to illustrate survival with and without hydroxyurea therapy. The Cox 
proportional-hazards regression model was used to estimate the hazard ratio and 
the 95% confidence interval (CI); the proportional hazards (PH) was checked (test 
and graphical diagnostics) by means of the scaled Schoenfeld residuals. The 
comparison between HU-treated and non-treated patients was done with the 
unpaired Wilcoxon test. In the Cox model the group of non-treated patients was 
compared with a subset of HU-treated patients with the age in the range of 25th and 
75th percentile of the age of no treated subjects. . All p-values were two-sided with 
the level of significance set at <0.05.  
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RESULTS 
 
Patients’ characteristics 
A total of 652 SCD patients who had received hyrdroxyurea were included in this 
analysis. The mean age at the time of hydroxyurea initiation was 24.5 ± 15.0 years 
(range: 1.0-67.0), with 32.7% of patients being in the pediatric age group (<18 
years). There was an equal gender distribution with 51.4% of patients being men. 
The majority of patients were of Caucasian (64.4%) or African (35.6%) origin; 
Supplementary Figure 1 illustrates the origins of patients analyzed in this study. 
Around half of the patients (46.6%) had a βS/βS genotype while the remaining 
patients had β0/βS (28.1%), β+/βS (22.1%), or other genotypes including βS/βC 
(3.2%). Patients’ characteristics are summarized in Table 1. 
 
Hydroxyurea therapy 
The median duration of hydroxyurea therapy in the study sample was 7 years 
(range: <1 year to 29 years). The wide range of treatment duration is related to the 
retrospective characteristic of this study. In fact, the large part of Caucasian patients  
started treatment many years ago since 1995. Whereas, pediatric subjects were 
placed under HU therapy after Baby HUG study [10,13] .  The mean therapeutic 
dose was 18.0 ± 4.7 mg/kg/day (range: 6.0-32.0). The distribution of dose categories 
was: <10 mg/kg/day (n/N=14/598, 3.2%), 10-20 mg/kg/day (n/N=434/598, 72.6%), 
and >20 mg/kg/day (n/N=150/598, 25.1%). Folic acid was concomitantly used in 
71.3% of patients (n/N=388/448). 
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Changes in laboratory parameters following hydroxyurea therapy 
Changes in laboratory parameters pre- and on-hydroxyurea therapy are summarized 
in Table 2. Hydroxyurea therapy was associated with a significant increase in mean 
total hemoglobin level (+0.5 g/dL, p<0.001). Hemoglobin increase was ≥1.0 g/dL in 
44.5% (n/N=125/490) of patients and was ≥2.0 g/dL in 19.0% (n/N=218/490) of 
patients. Hydroxyurea therapy was also associated with a significant increase in 
mean fetal hemoglobin level (+8.0%, p<0.001), while it was also associated with a 
significant decrease in mean hemoglobin S level (-7.3%, p=0.019). It was associated 
with a mean increase in mean corpuscular volume (+13.6 fL, p<0.001). Hydroxyurea 
therapy was also associated with a significant reduction in mean white blood counts 
(-2.3 x109/L, p=0.01) and platelets (-44.9 x109/L, p<0.001). Reticulocyte count also 
decreased although the change did not reach statistical significance. White blood 
counts <1.0 x 109/L were observed in three patients on hydroxyurea, while platelet 
counts <150 x109/L were documented in 77 patients although 19 (24.7%) of them 
already had counts <150 x109/L pre-hydroxyurea therapy. Hematological value in 
according to genotype are summarized in Table 3. Mean lactate dehydrogenase 
levels were significantly decreased on hydroxyurea therapy    (-161.3 IU/L, p<0.001), 
while bilirubin levels remained unchanged. A small but significant reduction was 
observed in mean aspartate aminotransferase level (-6.9 IU/L, p<0.001), while mean 
serum creatinine level was comparable pre- and on-hydroxyurea therapy Table 2.  
 
Changes in complication rates following hydroxyurea therapy 
Hydroxyurea therapy was associated with a significant reduction in the incidence of 
acute chest syndrome (-29.3%, p<0.001), vaso-occlusive crisis (-34.1%, p<0.001), 
hospitalization (-53.2%, p<0.001), and bone necrosis (-6.9%, p<0.001) (Table 4, 
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Figure 1). The median number of vaso-occlusive crisis per year was significantly 
lower on- compared with pre-hydroxyurea therapy (median: 3, range: 0-9 vs. median: 
1, range: 0-9; p<0.001). Similarly, the median number of hospitalization episodes per 
year was significantly lower on- compared with pre-hydroxyurea therapy (median: 2, 
range: 0-8 vs. median: 0, range: 0-4; p<0.001). The median number of acute chest 
syndrome episodes per year was also significantly lower on- compared with pre-
hydroxyurea therapy (median: 0, range: 0-8 vs. median: 0, range: 0-2; p<0.001). The 
median of silent cerebral infarctions was significantly higher compared with that pre-
hydroxyurea therapy (+42.4%, p<0.001); in particular 19% of patients with  normal 
MRI before the treatment had cerebral infarcts during HU therapy, and  81% of 
patients with previously detected SCI on MRI had a progression of cerebrovascular 
disease  with new SCI. In Table 5, incidence of SCI pre- and on-hydroxyurea 
according to the descent. The mean dosage of HU in patients with SCI was 16.4±5.2 
mg/Kg. Since ability to identify new silent cerebral infarction was restricted to 
patients who had underwent magnetic resonance imaging and hence naturally 
creating an imbalance between the number of patients with data pre- and on-
hydroxyurea; we carried out sensitivity analysis using only patients who had 
magnetic resonance imaging in ‘both’ periods (n=84).  No significant increase of 
stroke was observe (+0.5%, p=0.572), while silent infarcts were similar in both 
groups under hydroxyurea treatment, considering that patient sample was smallest 
in African descendent group.  
The remaining complications, such as leg ulcers or pulmonary hypertension were 
comparable in incidence pre- and on-hydroxyurea therapy (Table 4, Figure 1). In 
Table 5 and Figure 2, we show the  incidence of complications pre- and on-
hydroxyurea according to descent, age, genotype, duration on hydroxyurea . 
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The observed benefit in decreased incidence of acute chest syndrome, vaso-
occlusive crisis, and hospitalization was observed universally across all subgroups. 
The benefit in decrease incidence of bone necrosis was primarily seen in adults (≥18 
years), the βS/βS and βS/β+ genotypes, patients on higher hydroxyurea dose (≥15 
mg/kg/day) and not necessarily treated for long duration (<10 years); it was observed 
however in both Caucasian and African origins. The increased incidence in silent 
cerebral infarction was significant in adults, patients from Caucasian origin, and 
patients with βS/β0 and βS/β+ genotypes. It was also significant irrespective of dose, 
or duration of therapy (Table 5 and Figure 2). 
 
Safety 
Adverse events as reported by treating clinicians were documented in 31/567 (5.5%) 
of patients. These included cytopenia (n=21), rash (n=1), melanonychia (n=1), 
nausea and poor appetite (n=1), allergic reaction (n=1), skin ulcers (n=1), and 
thrombosis (n=1) [1 patient’s description was missing]. A total of 14/581 of patients 
(Table 6) developed cancer during hydroxyurea therapy (average age at cancer 
development 46.3 ± 13.1 years, median duration of hydroxyurea 10 years), 
corresponding to a tumor rate of 348 cases per 100,000 people versus the tumor 
rate of 385.1 cases per 100,000 people for Italian population reported by the 
International Agency for Research on Cancer (World Health Organization) 
(http://eco.iarc.fr/EUCAN/Cancer.aspx). All three patients who developed 
hepatocellular carcinoma had chronic hepatitis C infection, while one of the two 
patients developing lung cancer was a longtime heavy smoker. A total of 14 patients 
died during hydroxyurea therapy (all were ≥18 years, median duration on 
hydroxyurea was 10 years) (Table 6). A survival curve was constructed comparing 
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survival HU treated patients to a randomly selected group of 79 SCD patients (18 
deaths, 22.8%) who had never received hydroxyurea, with follow up from birth until 
31 December 2015, death, or loss to follow up (Figure 3). Because the two groups 
were not comparable for age (p<0.001) and in order to prevent the age-dependence 
of clinical complications [23]  the comparison was performed with the subset of 
treated patients (n= 214) whose age was in the range between 25th and 75th 
percentile of the age of no treated subjects (i.e. 32 - 52.5 years). The data of these 
comparable groups (p=0.86) were used in the Cox model: the hazard ratio for death 
in patients who had used hydroxyurea during their disease course compared to 
those who did not was 0.22 (95% CI,  0.08-0.6, p<0.0028). 
Regarding fertility, before HU administration only 30 men chose to store sperm  
 
samples. During the treatment sperm analysis showed azo/oligospermia  in 3 
 
patients. 
  
Forty-three women were reported to be pregnant during hydroxyurea therapy (30 
patients had one pregnancy, 11 had two pregnancies, and 2 had three pregnancies). 
Abortion in the first trimester of pregnancy was reported in 6 of the 58 pregnancies, 
while the remaining pregnancies continued through delivery with live births. 
Complications during pregnancy were reported in seven of the 43 patients. All 
mothers discontinued hydroxyurea treatment during their gestation as soon as the 
pregnancy test was positive and were switched to either packed red blood cell 
transfusion or an exchange regimen. Hydroxyurea was only resumed when their 
lactation period was completed. The incidence of infertility treatment was 20% in 
Italian population. 
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DISCUSSION 
This is the first large multicenter study in Southern European country, involving a 
large number of patients with different descent (Caucasian and Africans), referring to 
national comprehensive centers for hemoglobinopathies. 
Our data indicate that hydroxyurea therapy lowers the incidence and annual 
frequency of acute chest syndrome, painful vaso-occlusive crisis, and hospitalization 
through a large cohort of SCD patients with either Caucasian or African descent.  
Although established as a valuable therapeutic agent, in our study only 39.8 % of 
patients with SCD were treated with hydroxyurea. Other research suggests that 
hydroxyurea is underutilized in actual clinical practice for patients with SCD 
[23,24,25].  
Such benefits were observed across the spectrum of patient profiles, irrespective of 
age, origin, genotype, and the dose or duration of therapy. These data confirm 
previous findings from clinical trials and long-term follow-up [7-13], and further shed 
light on the role of hydroxyurea in real-life management of patients with SCD [7-13]. 
Our data reflected a hydroxyurea treatment initiation period which goes earlier than 
recent studies [26,27] , and thus may represent a more conservative approach to 
management restricted to severe or older patients, thus explaining why no more than 
half of the population had received the drug. Our cohort is also characterized by a 
large proportion of immigrants from endemic areas for SCD, who were able to start 
hydroxyurea following referral to SCD centers at a later stage in their disease. 
Nonetheless, our results indicating benefit in such a patient admixture further support 
the wider use of hydroxyurea [2]. 
In our cohort, the incidence of stroke on hydroxyurea therapy was comparable to that 
pre-hydroxyurea, but new silent cerebral infarction was detected during HU 
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treatment. The onset was more frequent in those who had previous SCI, in 
agreement with previous reports in different SCD population [28,30]. This is of 
interest because in our study, owing to the retrospective nature of our study and lack 
of TCD or magnetic resonance angiography data, it is difficult to realize the 
cerebrovascular profile of evaluated patients and offer a robust conclusion regarding 
stroke prevention, although the lack of increase in incidence should be reassuring. 
However, our observation further raises a call for addressing the current knowledge 
gap on the role of hydroxyurea in prevention of silent cerebral infarction especially 
that data from smaller reports illustrate absence of hydroxyurea’s role in this setting 
[29]. Moreover, through data stratification we were able to identify the subgroups at 
such increased risk of silent cerebral infarction and these included adult patients and 
those with sickle β-thalassemia which were either excluded or not adequately 
represented in recent trials [26-28]. The increased incidence of silent cerebral 
infarction with advancing age has been previously suggested [31]. The effect of co-
inheritance of β-thalassemia, however, merits further evaluation.  
 
We did not identify new types or higher incidence of adverse events on hydroxyurea 
therapy from those commonly published in the literature [13]. Considering that the 
majority of our cohort are adults, the observed rare cases of malignancy from various 
types are commensurate with what is observed in a surviving adult population [32].  
To date, there is also no established negative impact of hydroxyurea therapy upon 
fertility and no clinical evidence of teratogenicity, although reports of pregnancy 
experience on hydroxyurea are limited [13].  Although our study cannot clearly 
confirm absence of risks, it adds to those limited experiences and further data in this 
direction is needed. 
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Our study does not come without limitations. The retrospective nature of data 
imposes missing values that could alter exact estimates of incidence rates, although 
there is no reason to believe that such shortcoming was dominant in the pre- or on-
hydroxyurea periods. Moreover, several pathophysiologic markers and genetic 
factors that can alter the disease expression could not be evaluated or remain 
unknown, such data could have better characterized the patient profiles and the 
observed benefits or lack of in our cohort, some of which would have been altered 
within the natural course and regression to the mean. Our study did not evaluate 
compliance to therapy which could have implications on treatment effects. Lastly, 
certain peculiarities about the data analyzed herein, such as late onset of 
hydroxyurea start for some patients, indication often limited to what would be 
considered today severe cases, unbalanced exposure period before and on 
hydroxyurea, and potential under-dosing in some patient may not allow direct 
generalizability of results to other current patient populations.  
 
Our real-life experience not only represents the first published nation-wide 
experience from Europe but further confirms the broad benefit and safety of a widely 
available therapeutic option for the prevention of acute chest syndrome, vaso-
occlusive crisis, bone necrosis, and hospitalization in SCD, yet raises questions on 
its role in other disease manifestations. It also outlines some interesting clinical 
benefits, applicable to both children and adults, which are significant even with lower 
dosage than recommended and in subgroups which have been previously only 
scarcely been described in small studies like βS/β [31].   
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Table 1. Patients’ characteristics (n=628). 
Parameter Value 
Age in years, mean ± SD, median (range) 24.5 ± 15, 24.0 (range: 1.0-67.0) 
Age category in years, n/N (%)  
<18 209/554 (32.7) 
≥18 345/554 (67.3) 
Male, n/N (%) 320/622 (51.4) 
Origin, n/N (%)  
Caucasian* 400/621 (64,4) 
Africa** 221/621 (35.6) 
Genotype, n/N (%)  
βS/βS 277/594 (46.6) 
β
0
/βS 167/594 (28.1) 
β
+
/βS 131/594 (22.1) 
Other 19/594 (3.2) 
SD, standard deviation. 
*Caucasian: Albania, Saudi Arabia, India, Italy, Marocco, Tunisia 
**African: Angola, Benin, Brasile, Burkina , Burkina Faso, Burundi, Camerun, Cina-Portorico, Congo, 
Costa D’Avorio, Egypt, Ghana, Guinea, Nigeria, Panama, Dominican Republic, Republic of Congo, 
Santo Domingo, Senegal, Sierra Leone, Togo, Uganda, USA 
 
 
 
Table 2. Laboratory parameters pre- and on-hydroxyurea therapy. 
Parameter Pre-Hydroxyurea On-Hydroxyurea p-value 
Total Hb (g/dl) 9.2 ± 1.6 9.7 ± 1.5 <0.001 
HbF (%) 9.0 ± 8.0 17.0 ± 10.5 <0.001 
HbS (%) 64.4 ± 14.2 57.1 ± 14.0 0.019 
MCV (fL) 77.5 ± 9.9 91.1 ± 13.2 <0.001 
WBC (x10
9
/L) 12.1 ± 7.0 9.8 ± 13.5 0.001 
Reticulocytes (%) 9.9 ± 10.1 8.6 ± 11.1 0.180 
Platelets (x10
9
/L) 386.1 ± 179.1 341.3 ± 174.0 <0.001 
LDH (IU/L) 852.5 ± 954.2 691.2 ± 341.8 <0.001 
Total bilirubin (mg/dL) 6.6 ± 14.9 6.2 ± 14.9 0.212 
Direct bilirubin (mg/dL) 1.3 ± 2.4 1.3 ± 2.7 0.382 
AST (IU/L) 43.6 ± 23.3 36.7 ± 24.1 <0.001 
ALT (IU/L) 32.0 ± 25.3 34.2 ± 20.1 0.110 
Data presented as mean ± standard deviation. 
Hb, hemoglobin; MCV, mean corpuscular volume; WBC, white blood counts; 
LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. 
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Table 3. Laboratory parameters by genotype,  pre- and on-hydroxyurea therapy.  
Parameter 
 
Pre-Hydroxyurea 
 
On-Hydroxyurea p-value 
βS/βS βS/β0 βS/β+ βS/βS βS/β0 βS/β+ βS/βS βS/β0 βS/β+ 
Total Hb (g/dl) 8.5 ± 1.3 9.1 ± 1.2 10.5 ± 1.7 9.4 ± 1.4 9.5 ± 1.2 10.4 ± 1.5 <0.001 0.008 0.6 
HbF (%) 9 ± 7 10 ± 7 6 ± 5 15 ±  9 21 ± 12 15 ± 11 <0.001 <0.001 <0.001 
HbS (%) 61 ± 17 67 ± 14 66± 10 60 ± 14 54 ± 9 56 ± 12 0,34 0,004 0.004 
MCV (fL) 83  ± 10 73 ± 6 73 ± 7 95 ± 13 87 ± 11 86 ± 11 <0.001 <0.001 <0.001 
WBC (x10
9
/L) 13 ± 8 12 ± 5 10± 6 10 ± 4 11 ± 23 8 ± 4 <0.001 0.7 <0.001 
Reticulocytes (%) 14 ± 12 8 ± 5 9 ± 11 8 ± 11 7 ± 8 10 ± 15 0.013 0.7 0.8 
Platelets (x10
9
/L) 402 ± 163 404 ± 188 358 ± 227 360 ± 167 355 ± 167 320 ± 181 0.003 <0.001 0.1 
Data presented as mean ± standard deviation. 
Hb, hemoglobin; MCV, mean corpuscular volume; WBC, white blood counts 
 
 
Table 4. Incidence of new complications pre- and on-hydroxyurea therapy. 
Complication Pre-Hydroxyurea On-Hydroxyurea 
Incidence 
difference 
p-value 
Stroke 17/620 (2.7) 20/622 (3.2) +0.5% 0.572 
Silent cerebral infraction 32/189 (16.9) 51/86 (59.3) +42.4% <0.001 
Acute chest syndrome 227/556 (40.8) 69/598 (11.5) -29.3% <0.001 
Vaso-occlusive crisis 501/555 (90.3) 336/598 (56.2) -34.1% <0.001 
Hospitalization 343/433 (79.2) 159/612 (26.0) -53.2% <0.001 
Pulmonary hypertension 14/484 (2.9) 9/353 (2.5) -0.4% 0.210 
Leg ulcers 28/498 (5.6) 28/619 (4.5) -1.1% 1.000 
Bone necrosis 103/417 (24.7) 61/343 (17.8) -6.9% <0.001 
Chronic renal disease 17/474 (3.6) 13/320 (2.1) -1.5% 0.774 
All data presented as n/N (%). 
 
Table 5. Incidence of complications pre- and on-hydroxyurea (HU) according to the descent. 
Complication 
Caucasian African 
pre-HU on-HU p-value pre-HU on-HU p-value 
Stroke 
15/400 
(3.8%) 
20/396 
(5.1%) 
- 
2/220 
(0.9%) 
0/220 
(0%) 
- 
Silent cerebral 
infarction 
26/147 
(17.7%) 
49/83 
(59%) 
<0.001 
6/42 
(14.3%) 
2/3 
(66.7%) 
<0.001 
Acute chest syndrome 
146/357 
(40.9%) 
56/379 
(14.8%) 
<0.001 
81/199 
(40.7%) 
13/218 
(6.0%) 
<0.001 
Vaso-occlusive crisis 
330/346 
(95.4%) 
230/392 
(58.7%) 
<0.001 
171/208 
(82.2%) 
107/205 
(52.2%) 
<0.001 
Hospitalization 
243/312 
(77.9%) 
106/392 
(27.0%) 
<0.001 
99/120 
(82.5%) 
53/219 
(24.2%) 
<0.001 
Pulmonary 
hypertension 
14/335 
(4.2%) 
8/314 
(2.5%) 
- 
0/149 
0% 
1/38 
2.6% 
- 
Leg ulcers 
27/348 
(7.8%) 
26/399 
(6.5%) 
- 
1/150 
(0.7%) 
2/219 
(0.9%) 
- 
Bone Necrosis 
85/336 
(25.3%) 
60/304 
(19.7%) 
<0.05 
18/81 
(22.2%) 
1/37 
(2.7%) 
<0.05 
Chronic  Kidney 
disease 
16/329 
(4.9%) 
12/281 
(4.3%) 
- 
1/145 
(0.7%) 
0/37 
(0%) 
- 
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Table 6. Causes of death and cancer cases during hydroxyurea therapy. 
Cause of death n 
Acute chest syndrome 4 
Lung cancer 2 
Pulmonary embolism 1 
Hemorrhagic stroke 1 
Live failure 1 
Parvovirus infection in hepatic failure 1 
Hepatocellular carcinoma 1 
cardiac failure 1 
Pulmonary hypertension 1 
Infection 1 
Cancer type n 
Hepatocellular 3 
Breast 3 
Lung 2 
Nasopharyngeal 1 
Laryngeal 1 
Colon 1 
Thyroid 1 
Adrenal 1 
Lymphoproliferative 1 
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FIGURE LEGENDS 
Figure 1. Incidence of complications pre- and on-hydroxyurea. A significant 
reduction in the incidence (p<0.001) was found in complications: acute chest 
syndrome (-29.3%), vaso-occlusive crisis (-34.1%), hospitalization (-53.2%), bone 
necrosis (-6.9%); an increase was found in silent cerebral infarction (p<0.001, 
+42.3%). 
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Figure 2. (A) Incidence of complications pre- and on-hydroxyurea according to the 
age of patients (i.e. patients with age ≤ 18 years and ≥ 18 years): a significant 
decrease (p<0.001) was found in acute chest syndrome (-29,7% and -26%), vaso-
occlusive crisis (-31.8% and -38.9%) and hospitalization (-67% and -51.2%); an 
increase was found in silent cerebral infarction (+41.7%, p<0.001) of adult patients. 
(B) Incidence of complications pre- and on-hydroxyurea according to the genotypes 
βS/βS, βS/β0 and βS/β+: a significant decrease (p<0.001) of the incidence was found 
in all genotype for acute-chest syndrome, vaso occlusive crisis and hospitalization, a 
significant increase (p<0.001) was found for silent cerebral infarction for groups 
βS/β0 and βS/β+, an increase in stroke (p<0.05) for group βS/β+. (C) Incidence of 
complications pre- and on-hydroxyurea according to the hydroxyurea (HU) duration 
(i.e. < 10 years  and ≥ 10 years): a decrease (p<0.001) of the incidence was found 
for acute-chest syndrome, vaso-occlusive crisis and hospitalization, an increase was 
found in silent cerebral infarction (p<0.001) for both HU durations; a decrease 
(p<0.05) was found in necrosis for HU duration < 10 years.   
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Figure 3. Kaplan Meier curves shows the survival for patients treated with 
hydroxyurea (n=214) and no treated with hydroxyurea (n=79). The two survival 
curves are significantly different from each other (p=0.0012): patients receiving 
hydroxyurea have significantly better survival in comparison to those without. 
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